p21(waf1/cip1) protein expression in normal, hyperplastic and malignant endometrium. Correlation with hormone receptor status, c-erbB-2 oncoprotein, bcl-2 and other cell cycle related proteins (Rb, p53, Ki-67, PCNA)

Experimental Oncology

Volumn 25, Issue 3, 2003, Pages 200-205

  Ioachim, E ^a   Kitsiou, E ^b   Mitselou, A ^a   Zagorianakou, N ^a   Charalabopoulos, K ^a   Salmas, M ^c   Makrydimas, G ^a   Vougiouklakis, Th ^a   Agnantis, N J ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b G Hatzikosta Hospital   (Greece)

^c NONE

Author keywords

Endometrial lesions; ER; Ki 67; P21 (waf1 cip1); P53; PCNA; PR; Rb

Indexed keywords

CELL CYCLE PROTEIN; CYCLINE; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ABDOMINAL HYSTERECTOMY; ADULT; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; GYNECOLOGIC CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MENOPAUSE; ONCOGENE C ERB; PROTEIN EXPRESSION; SALPINGOOOPHORECTOMY; TUMOR SUPPRESSOR GENE; ENDOMETRIUM CANCER; UNIVARIATE ANALYSIS;

EID: 0142118407     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51: 6304-11.
2. Shaw P, Bovey R, Tardy S, Schli R, Jordat B, Costa J. Induction of apoptosis by wild-type p53 in human colon-derived cell line. Proc Natl Acad Sci USA 1992; 89: 4495-9.
3. El-Deiry WS, Tokino T, Velculeseu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-25.
4. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE, Givol D. Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 1994; 54: 3391-5.
5. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-dependent mechanism. Proc Natl Acad Sci USA 1995; 92: 5545-9.
6. Johnson M, Dimitrov D, Vojta PJ, Barrettt JC, Noda A, Pereina-Smith OM, Smith JR. Evidence of a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 mRNA in human cells. Mol Carcinogenesis 1994; 11: 59-64.
7. Zing Y, EL-Deiry WS. Regulation of p21 waf1/Cip1 expression by p53- independent pathways. Oncogene 1996; 12: 1557-64.
8. Ito K, Sasano H, Matsunaga G, Sato S, Yasima A, Nasim S, Garret CT. Correlation between p21 expression and clinicopathological findings. p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 1997; 183: 318-24.
9. Salvesen HB, Iversen OE, Akslen LA. Prognostic significance of angiogenesis and ki-67, p53, and p21 expression: a population-based endometrial carcinomas study. J Clin Oncol 1999; 17: 1382-90.
10. Burton JL, Stewart RL, Heatley MK, Royds JA, Wells M. p53 expression, p21 expression and the apoptotic index in endometrioid endometrial adenocarcinoma. Histopathology 1999; 35: 221-9.
11. Backe J, Gassel AM, Hauber K, Krebs S, Bartek J, Cattier H, Kreipe HH, Muller-Hermenlink HK, Dietl J. p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 1997; 16: 361-8.
12. Milde-Langosch K, Bamberger AM, Goemann C, Rossing E, Rieck G, Kelp B, Loning T. Expression of cell-cycle regulatory proteins in endometrial carcinomas: correlations with hormone receptor status and clinicopathologic parameters. J Cancer Res Clin Oncol 2001; 127: 537-44.
13. Saegusa M, Machida D, Okayasu I. Age-dependent differences in tumor cell polarity in endometrial carcinomas. J Cancer Res Clin Oncol 2002; 128: 205-13.
14. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. Br J Cancer 1996; 74: 208-15.
15. Marchetti A, Doglioni C, Barbareschi M, Buttitta F, Pellegrini S, Bertacca G, Chella A, Merlo G, Angeletti CA, Dalia Palma P, Bevilacqua G. p21 RNA and protein expression in non-small cell lung carcinomas: evidence of p53-independent expression and association with tumoral differentiation. Oncogene 1996; 12: 1319-24.
16. DiGiuseppe JA, Redston MS, Yeo CJ, Memse SE, Uruban RH. p53 independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995; 147: 884-8.
17. FIGO stages - 1988 revisions. Gynecol Oncol 1989; 35: 125-7.
18. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577-80.
19. Sung CJ, Zheng Y, Quddus MR, Kang X, Zhang ZF, Lauchlan SC, Zheng W. p53 as a significant prognostic marker in endometrial carcinoma. Int J Gynecol Cancer 2000; 10: 119-27.
20. Segreti EM, Novotny DB, Soper JT, Mutch DG, Creasman WT, McCarty KS. Endometrial cancer histologic correlates of immunohistochemical localization of progesterone and estrogen receptor. Obstet Gynecol 1989; 73: 780-5.
21. EL-Deiry WS, Tokino T, Waldman T, Oliner JD, Velculescu VE, Burell M, Hill DE, Healy E, Ress JL, Hamilton SR. Topological control of p21 WAF1/CIP1 expression in normal and neoplastic tissue. Cancer Res 1995; 55: 2910-9.
22. Bukholm IK, Nesland JM, Karesen R, Jacobsen U, Borresen AL. Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J Pathol 1997; 181: 140-5.
23. Jahnson S, Karlsson MG. Tumour mapping of regional immunostaining for p21, p53, and mdm2 in locally advanced bladder carcinoma. Cancer 2000; 89: 619-29.
24. Kleine W, Maier T, Geyer H, Pfleiderer A. Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance. Gynecol Oncol 1990; 38: 59-65.
25. Creasman WT. Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993; 71: 1467-70.
26. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK. Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 2002; 62: 881-6.
27. Morris PC, Anderson JR, Anderson B, Buller RE. Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol 1995; 56: 406-11.
28. Waga S, Hannon GJ, Beach D, Stillman B. The p21 inhibitor of cyclin dependent kinases controls DNA replication by interaction with PCNA. Nature 1994; 369: 574-8.
29. Hamel NW, Sebo TJ, Wilson TO, Keeney GL, Roche PC, Suman VJ, Hu TC, Podratz KC. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996; 62: 192-8.
30. Heffner HM, Freedman AN, Asirwatham JE, Lele SB. Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial adenocarcinoma. Eur J Gynecol Oncol 1999; 20: 8-12.
31. Lundgren C, Auer G, Frankendal B, Moberger B, Nilsson B, Nordstrom B. Nuclear DNA content, proliferative activity, and p53 expression related to clinical and histopathologic features in endometrial carcinoma. Int J Gynecol Cancer 2002; 12: 110-8.
32. Powell B, Soong R, Grieu F, Knowles S, Hammond I, Iacopetta B. p53 protein overexpression is a prognostic indicator of poor survival in stage I endometrial carcinoma. Int J Oncol 1999; 14: 175-9.
33. Niemann TH, Yilmaz AG, McGaughy VR, Vaccarello L. Retinoblastoma protein expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 1997; 65: 232-6.
34. Nielsen LA, Nyholm HJC. The expression of p53 protein, c-erbB-2 protein (p185) in endometrial adenocarcinomas of endometrioid type. An immunohistochemical examination on paraffin sections. Am J Clin Pathol 1994; 102: 76-9.
35. cip1/waf1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-84.
36. Poyak K, Waldman T, He TC, Kinzler KW, Vogelstein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev 1996; 10: 1945-52.
37. Makri D, Schulz WA, Grimm M, Clasen S, Bojar H, Schmitz-Drager BJ. WAF1/p21 regulates proliferation, but does not mediate p53-dependent apoptosis in Urothelial carcinoma cell lines. Int J Oncol 1998; 12: 621-8.